Table 1 Characteristics of primary AML samples.
Patient | Age at Collection | Prior treatment | PB vs BM | Morphologic blast% pre-processing | Type of processing (Ficoll vs Ficoll + CD3/CD19 depletion) | CG | Mutational profile | ELN 2022 risk status |
|---|---|---|---|---|---|---|---|---|
432 | 69 | No | PB | 94% | CD3-/CD19- | diploid | NPM1, TET2, FLT3-ITD | I |
992 | 26 | No | PB | 90% | CD3-/CD19- | diploid | NPM1, FLT3-ITD, DDX41, GATA2 | I |
390 | 45 | No | PB | 79% | CD3-/CD19- | -X | FLT3-ITD, DNMT3A | I |
114 | 39 | No | PB | 71% | Ficoll | diploid | NPM1, FLT3-ITD, DNMT3A | I |
988 | 27 | No | BM | 83% | CD3-/CD19- | del5 | FLT3-ITD, WT1 | A |
964 | 44 | 7 + 3, HiDAC | BM | 67% | Ficoll | diploid | FLT3-ITD, IDH2, NPM1 | I |
118 | 40 | 7 + 3, HiDAC | BM | 55% | CD3-/CD19- | diploid | NPM1, SRSF2 | A |
444 | 72 | No | BM | 50% | CD3-/CD19- | del5 | DNMT3A, IDH2 | A |
650-7 | 53 | 7 + 3 + GO | PB | 44% | CD3-/CD19- | inv(3), del7 | PTPN11 | A |
650-1.7 | 55 | 7 + 3 + GO, HiDAC + idasanutlin, AZA/ipilimumab/nivolumab, AZA/VEN/GO, FLAG-Ida/VEN/gilteritinib, CYC065/VEN, BIDFA | BM | 90% | Ficoll | inv(3), del7 | PTPN11 | A |
382 | 46 | No | PB | 79% | CD3-/CD19- | inv(3), del7 | KRAS, ASXL1 | A |
780 | 36 | No | PB | 70% | Ficoll | inv(3), del7 | PTPN11, KIT, BCOR, RUNX1 | A |
630 | 30 | No | PB | 63% | Ficoll | diploid | FLT3-ITD, KIT, TET2, WT1 | I |
1988 | 27 | No | PB | 77% | Ficoll | t(4;9) | FLT3-ITD, NRAS, ABL1 | I |
